155431-35-9

Upstream product

• 3473-63-0 formamidine acetic acid 
• 144172-28-1 N-(4-trifluoromethoxyphenyl)hydrazinecarboxamide 
• 155432-10-3 phenyl N-[4-(trifluoromethoxy)phenyl]carbamate 
• 150802-96-3 (2S,3R)-3-(2,4-Difluorophenyl)-3,4-epoxy-2-butanol 

Downstream Products

• 168969-20-8 2-[(1R,2R)-2-(2-fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-(4-trifluoromethoxyphenyl)-3(2H,4H)-1,2,4-triazolone 
• 155431-36-0 2-[(1R,2S)-2-(2,4-difluorophenyl)-2,3-epoxy-1-methylpropyl]-4-(4-trifluoromethoxyphenyl)-3(2H,4H)-1,2,4-triazolone 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δDual Agonists for the Treatment of Nonalcoholic Steatohepatitis

Peroxisome proliferator-activator receptors α/δ(PPARα/δ) are regarded as potential therapeutic targets for nonalcoholic steatohepatitis (NASH). However, PPARα/δdual agonist GFT-505 exhibited poor anti-NASH effects in a phase III clinical trial, probably due to its weak PPARα/δagonistic activity and poor metabolic stability. Other reported PPARα/δdual agonists either exhibited limited potency or had unbalanced PPARα/δagonistic activity. Herein, we report a series of novel triazolone derivatives as PPARα/δdual agonists. Among them, compound H11 exhibited potent and well-balanced PPARα/δagonistic activity (PPARα EC50 = 7.0 nM; PPARδEC50 = 8.4 nM) and a high selectivity over PPARγ(PPARγEC50 = 1316.1 nM) in PPAR transactivation assays. The crystal structure of PPARδin complex with H11 revealed a unique PPARδ-agonist interaction. H11, which had excellent PK properties and a good safety profile, showed potent in vivo anti-NASH effects in preclinical models. Together, H11 holds a great promise for treating NASH or other inflammatory and fibrotic diseases.

Optically active antifungal azoles. VI. Synthesis and antifungal activity of N-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl) propyl]-N′-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones

A new series of optically active antifungal azoles, N-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl) propyl]-N′-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones (1,2) and 5(1H,4H)-tetrazolones (3), were prepared from the triflate derivative of (1S)-1-[(2R)-2-(2,4-difluorophenyl)-2-oxiranyl]ethanol (13) by an SN2 displacement reaction with the union of an azolone (17-19) and subsequent ring-opening reaction with 1H-1,2,4-triazole. The optically active oxiranylethanol 13 was synthesized from methyl (R)-lactate in a stereocontrolled manner. The azolones 1-3 prepared showed potent antifungal activities in vitro and in vivo.

Azole compounds, their production and use

An azole compound represented by the formula (I): STR1 wherein Ar is a substituted phenyl group; R1 and R2 independently are a hydrogen atom or a lower alkyl group, or R1 and R2 may combine together to form a lower alkylene group; R3 is a group bonded through a carbon atom; R4 is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; and n Y and Z independently are a nitrogen atom or a methine group which may optionally be substituted with a lower alkyl group, or a salt thereof, which is useful for prevention and therapy of fungal infections of mammals as antifungal agent.